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Abstract: The discovery of stem cells heralded great improvements in the prognosis of a number of patients, 
in particular those having haematological diseases, the classic example being, of course leukaemia. After these 
encouraging results, scientists are researching ways of manipulating stem cell technology in order to treat more 
effectively diseases which decimate affluent societies following the epidemic of obesity, such as cardiovascular 
diseases for example. Furthermore, recent studies give hope in the fight against autoimmune diseases, as well 
as sickle-cell anaemia, even going some way towards outlining methods of providing a cure, hopefully in the 
not-too-distant future. 
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INTRODUCTION 
Stem cells are defined as clonogenic self-renewing 
progenitor cells that have the ability to divide from an 
indefinite period and can give rise to one or more 
differentiated cell types (Vejjajiva, 2002). This ability is 
known as developmental plasticity and as Table 1 shows, 
differs in the different types of stem cells. 
Leukaemia 
Non Hodgkin's Lymphoma (NHLl: Traditioml methods of 
treating NHL involve transplants of stem cells obtained 
from bone marrow, after high doses of chemotherapeutic 
drugs which kill off the patient's bone marrow. However, 
nowadays, stem cells can also be collected from peripheral 
blood, which has the advantages of not requiring to 
anaesthetise the patient in order to recover the cells and 
the blood COlllltS may potentially recover faster after 
chemotherapy. 
Peripheral Blood Stem Cell Transplants (PBSCT) 
have been shown to be effective in aggressive cases of 
lymphoma, which does not respond to treatment or 
which is likely to come back (although the patient is in 
remission). Such patients, who effectively have poorer 
prognoses, can achieve complete remission after 
marrow-ablative chemotherapy, followed by PBSCT 
(Kirita et aI., 2000). 
Comparisons between the pros and cons of 
PBSCT versus those of bone marrow transplant show 
that the former has an advantage over bone marrow 
transplantation in terms of neutrophil recovery and 
this can possibly be applied to platelet engraftment 
(Lewis, 2005). 
• 
• 
Stem cell transplants can be divided into: 
Autologous transplants, where stem cells are 
obtained from the patient and reinjected after 
marrow-ablative chemotherapy. 
Allogenic transplants, where stem cells are obtained 
from a donor (may be a sibling, or even a non-related 
donor), who is fOlllld out to be a match. This type of 
transplant is sometimes done if the patient has a 
relapse after an autologous transplant, in order to 
avoid retwning the patient's own cancerous cells. 
However, it is worth noting that allogeneic 
transplants have more side effects and complications 
and the number of people suitable for this treatment 
is restricted. 
Research is still being carried out to establish the 
pros and cons of the 2 protocols. 
Acute Myeloblastic Leukaemia (AML): Treatment for 
A1.1L follows basically the same pattern as for NHL. In 
this case, the safety and efficacy of myeloablative 
therapy followed by autologous PBSCT was 
demonstrated as early as in 1997 by Gondo's team who 
studied 60 patients suffering from A11L (Gondo et al., 
1997). High-dose chemotherapy consisting of busulfan 
(16 mg kg-'), etoposide (40 mg kg-') and cytosine 
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Table 1: A comparison of the different types of stem cells in terms of their plasticity 
Level of plasticity 
Totipotent 
Pluripotent 
Pluripotent 
Pluripotent to multipotent 
Type of cells 
Zygote 
a) Embryonic Stem Cells (ES cells) 
b) Umbilical Stem Cells 
Adult Stem Cells 
a) Haematopoeitic stem cells 
b) Mesenchymal stem cells 
Cell types obtainable 
All cell types-develops into embryo 
All cell types-does not develop into an embryo 
Same as ES cells 
Red, white blood cells, imrmme cells, others? 
Lipocytes, cartilage, bone, tendon and ligaments, my ocytes, 
skin cells, neurons 
c) Others (methods of collection still not very well-characterized) Neurons, hepatocytes, pnelllllocytes .. 
Crossing of germ layers d) Transdifferentiation (occurs ooder special conditions) 
arabinoside (3 g/m 2x4) (BEA regimen) was used for 
pretransplant conditioning in 13 patients, whereas for the 
remaining 47 patients, growth factors (for example 
Granulocyte Colony-Stimulating Factor (G-CSF) were 
administered during conditioning. 
This study as followed by others. notably de la 
Rubia's in 1999 which compared the clinical results of two 
consecutive protocols including Autologous Blood Stem 
Cell Transplantation (ABSCT) for patients with de novo 
AJ\.1l, in first complete remission (Rubia et al., 1999). In the 
first one (group A-20 patients). PBSC were collected after 
induction and consolidation chemotherapy courses and 
ABSCT was performed immediately thereafter. In the 
subsequent 25 patients (Group B), PBSC were collected 
after consolidation alone and a further chemotherapy 
course with intermediate dose cytarabine (Ara-C 1 
g/m2112 hx3 days) and mitoxantrone (l2mg/m2/ dx3 days) 
was administered as early intensification. From the results 
obtained, it was noted that haematopoietic engraftment 
was slightly quicker in Group B. Furthermore, autologous 
transplants with PBSC collected after consolidation 
chemotherapy were still associated with a high Rate of 
Relapse (RR). Having said tha~ the actuarial 4-year 
Disease-Free Survival (DFS) was not significantly 
different between the 2 groups (32 v 18%). 
AUTOIMMUNE DISEASES 
Multiple Sclerosis (M:S): Widespread demyelination is a 
hallmarks of MS. The multifocal nature of this chronic 
inflammatory disease of the central nervous system 
complicates cellular therapy and puts emphasis on both 
the donor cell origin and the route of cell transplantation. 
In 2003, an Italian research team established syngenic 
adult neural stem cell cultures and injected them into an 
animal model of MS (Experimental Autoimmlllle 
Encephalomyelitis (EAE) in the mouse) using either of 2 
protocols; intravenously or intracerebroventricularly. In 
both cases, significant mnnbers of donor cells entered 
into demyelinating areas of the central nervous system 
and differentiated into mature brain cells. Within these 
areas, oligodendrocyte progenitors markedly increased, 
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with many of them being of donor origin and actively 
remyelinating axons. Furthermore, a significant decrease 
of astrogliosis and a marked reduction in the extent of 
demyelination and axonal loss were observed in 
transplanted animals, when these animals were studied 
using 1.1Rl, after using iron to magnetically label neural 
stem cells of adult mice. The fllllctional impairment caused 
by EAE was almost abolished in transplanted mice, both 
clinically and neurophysiologically, leading to hopes that 
stem cell transplants could be the answer towards finding 
a cure for MS (Pluchino e/ 01 .• 2003). 
Systemic Lupus Erythomatosus (SLE): SLE is a chronic 
inflammatory disorder that can involve any organ system, 
but most commonly affects joints, skin and kidneys. 
Research has suggested autologous haemopoeitic stem 
cell transplants preceded by high-dose chemotherapy can 
arrest progression of severe autoimmlllle diseases. 
Between 1995 and 2003. A Gratwohl and his tearn 
evaluated the toxicity and disease response in 473 
patients with severe autoimmlllle disease treated with 
autologous HSCT (Gratwohl e/ 01.. 2005) by noting 
survival, transplant-related mortality, treatment response 
and disease progression in the said patients. The results 
were fOlllld to support the hypothesis that autologous 
HSCT can alter disease progression in severe autoimmlllle 
disease. 
In fact, experimental data and early phase liII studies 
where SLE was treated with aulologous HSCT gave 
promising results (Burt e/ 01 .• 2003). Unfortunately. climcal 
trials phase II performed in the past, have shown high 
morbidity and mortality, which was to be expected in a 
population already at increased risk for thrombosis, 
vasculitis and atherosclerosis. 
Juvenile Chronic Arthritis (JCA): The logic behind 
using stem cells transplants for JCA is identical to that 
used for other autoimmlllle diseases. Since the patient's 
immlllle system attacks ths patien's body, the logic is that 
the patient is given a large dose of chemotherapy to kill 
off defective cells and AHSCT is used to fwnish the 
patient with a newly minted immlllle system. 
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F or this particular disease, things appear to have 
advanced quite a lot with a successful clinical trial being 
reported quite some time ago in 1999, in The Lancet. In 
this experiment, four children with severe forms of JeA 
treated withAHSCT. Of these four patients, three children 
had systemic JCA and one child had polyarticular JCA. 
One month before AHSCT, llllprimed bone marrow was 
taken, after which T-cell depletion of the graft was done 
with CD2 and CD3 antibodies. A preparative regimen of 
antithymocyte globulin (20 mg kg-'). cyclophosphamide 
(200 mg kg-') and low-dose total body irradiation (4 Gy) 
were used to destroy the patients' immlllle system. 
Methotrexate and cyclosporin were stopped before 
AHCST while prednisone was tapered after 2 months. 
(Wulffraat elol.. 1999). 
From the results obtained, it was shown that patients 
showed a drug-free follow-up of 6-18 months with a 
marked decrease in joint swelling, pain and morning 
stiffness. Erythocyte Sedimentation Rate (ESR). C-
Reactive Protein (CRP) and Hb retllllled to almost normal 
values within 6 weeks. In spite of the T-cell depletion, 
there was a rapid immlllle reconstitution in three out of 
four children. AS is the case whenever patients are 
immllllosuppressed and even more so in cases like this 
where the immlllle system is destroyed, patients are very 
vulnerable to infection. In fact, in this experiment, 2 
patients developed a limited varicella zoster virus 
eruption, which was treated by aciclovir (Wulffraat et al., 
1999). 
This successful research project demonstrated that 
AHSCT for severe JCA was well tolerated and induced a 
remission of disease in four children with JCA that was 
resistant to conventional treatment (Wulffraat et al., 
1999). 
CARDIOVASCULAR DISEASE 
Myocardial Infarctions (MI): In 2004, cardiologist Joshua 
Hare and his team presented results from an animal study 
conducted at J olms Hopkins, which showed that stem cell 
therapy can be used effectively to treat 1.1Is in pigs. Stem 
cells were taken from another pig's bone marrow and 
injected into the animal's damaged heart and it was fOlllld 
that they were able to restore the heart's fllllction to its 
origiml condition (Hare el 01.. 2005). 
In a controlled study of 14 pigs, seven received 
therapy and another seven received only a placebo. The 
researchers fOlllld that injections of BMSC directly into 
heart muscle, recently damaged by an 1.1I, produced a 
nearly full recovery after 2 months. 
Recovery was measured for the seven treated animals 
as full restoration of heart muscle contraction to levels 
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existing prior to infarction. Indeed, dead scar tissue was 
reported to have nearly disappeared after therapy and 
only a small trace of the 1.1I was left. 
In contrast, for the seven animals in the control 
group that did not receive therapy, no recovery was 
observed and the animals' condition worsened, leading to 
the development of congestive heart failure within two 
months after the MI (Hare el 01 .• 2005). 
While on the one hand this news appears to be short 
of miraculous, recently 3 separate studies appeared in the 
New England J olllllal of Medicine, which appeared to 
discredit this evidence, reporting that there was little 
evidence to justify the administration of adult stem cells 
to 1.1I patients. 
In a study led by Dr. Lllllde, patients with acute 1.1I 
of the anterior wall treated with percutaneous coronary 
intervention, were randomly assigned to the group that 
lllldeIWent intracoronary injection of autologous BMSC 
or to the control group, in which neither aspiration nor 
sham injection was performed. Electrocardiogram-gated 
Single-Photon-Emission Computed Tomography (SPECT) 
and echocardiography at baseline and Magnetic 
Resonance Imaging (J\.1Rl) were used 2-3 weeks after the 
infarction to assess left ventricular fllllction. These 
procedures were repeated 6 months after the MI. 
Results obtained in this study showed that BMSCT 
after 1.1Is did not significantly effect the patients in the 
study, given that 2 groups did not differ significantly in 
changes in left ventricular end-diastolic vohnne or infarct 
size and had similar rates of adverse events (Lllllde et al., 
2006). 
This result was echoed by 2 separately conducted 
studies, published in the same jOlllllal, namely one led 
by Schachinger el 01. (2006) and another led by 
Assmus elol. (2006). 
All 3 studies made use of protocols which were 
scientifically correct, thus lllldermining support for 
stopping ES cell research, given that the results obtained 
by adult stem cells are highly questionable, when seen in 
this light. 
Stroke: Treatment for stroke aims to restore fllllction in 
the diseased hwnan brain by replacing dead neurons with 
new neurons through transplantation or stimulation of 
neurogenesis from endogenous stem/precursor cells. To 
repair the hwnan brain after stroke may seem impossible 
because of the atrophy and loss of many different neuron 
and glial cell types. However, it can be argued that 
reestablishment of even only a fraction of damaged 
neuronal circuitries might have significant implications. 
CWTent research gives quite encouraging results in 
that the newly generated neurons were fOlllld to be able 
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to migrate toward the damage and adopt the phenotype of 
those cells that have died, at least to some extent, as 
demonstrated in 2 different studies (Modo e/ al.. 2002; 
Arvidsson e/ al.. 2002). 
Having said that, it is important to note that many 
basis issues remain to be solved, such as for example the 
mechanism on endogenous repair which occurs after 
stroke, how to control stem cell proliferation and 
differentiation into specific phenotypes, induce their 
integration into existing neural and synaptic circuits and 
to optimize the fllllctional recovery in animal models of 
stroke (Lindvall and Kokaia. 2004). 
SICKLE CELL ANAEMIA 
In this field, research is moving at a fast pace in 
quite a mnnber of different therapy. In fact, haemopoeitic 
blood transfusions (using stem cells obtained from the 
bone marrow) were the first line of research. Such 
transfusions require siblings who are a good genetic 
match. This led to researchers looking into stem cell 
transplants using US cells from wrrelated donors. 
Vichinsky (2002) in fact. managed to perform this with 
apparent success meaning that this approach has turned 
outto be quite promising. 
Statistics in fact, show that about 150 children 
worldwide have had blood stem cell transplants and 
about 85% of them appear to be cured of the disease. It is 
important to note however, that this approach carries a 
high risk: About 5% of children who lllldeIWent bone 
marrow transplants died while the transplant failed in 
another 10% (data obtained from the National Institutes 
of Health. Hematopoietic Cell Transplantation, in 
Management of Sickle Cell Disease. NIH Publication 
Number 02-2117. revised May 28. 2002. accessed 4/19/04). 
Finally, it is worth noting a novel approach 
lllldertaken by team of scientists at Memorial Sloan-
Kettering Cancer Centre, who have combined gene 
therapy with stem cell research and RNA interference in 
an attempt to genetically reverse sickle cell disease in 
hwnan cells. Adult stem cells were obtained from sickle 
cell patients and were cultured in the lab. A viral vector 
was constructed to that it carried a therapeutic globin 
gene, harbouring a small interfering RNA precursor 
specific for beta S-globin and designed to suppress 
abnormal Haemoglobin (Hb) formation. The vector was 
introduced in the cell culture, resulting in suppression of 
the production of HbS and leading to the production of 
normal Hb in RBCs (Samakoglu e/ al .• 2006). 
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CONCLUSION 
While acknowledging that great advances have been 
made, especially with regard to blood and the circulatory 
system, it is important to realize that there are still great 
obstacles to overcome before some of the therapies 
highlighted out by experimental evidence available today, 
become a reality. Furthermore, stem cell therapies need to 
be made commercially viable before they can be used to 
treat the general public. 
Having said that, stem cells therapies offer hope to 
patients of diseases for which there is cWTentiy no cure, 
in manner of more effective treatment or even, for some 
diseases, offering a cure; hence resulting inevitably in a 
better quality of life for the both patient and the people 
sWTollllding himiher. 
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